Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

Different types of antibodies are produced by your immune system. These five antibodies help fight disease by detecting viruses, bacteria, and other pathogens (disease-causing microorganisms) and ...

Sjögren’s antibody testing is done using a blood sample. It checks antibody levels, including anti-SS-A (also called anti-Ro) and anti-SS-B (also called anti-La). Anti-SS-A and anti-SS-B are ...

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.

When I look for the best cloud storage for photos, I always look for services that offer plenty of storage space for high-definition photos with secure online backups at a reasonable price.

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...

and our differentiated anti-PD-L1/-VEGF-A bispecific antibody candidate BNT327/PM8002 for the treatment of advanced cancers. With our capabilities, we believe BioNTech is uniquely positioned to ...